HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Enalaprilat (Vasotec)

Subscribe to New Research on Enalaprilat

The active metabolite of ENALAPRIL and a potent intravenously administered angiotensin-converting enzyme inhibitor. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.

Also Known As:

Vasotec; Biovail Brand of Enalaprilat Anhydrous; Boehringer Ingelheim Brand of Enalaprilat Anhydrous; Enalapril-TEVA; Enalaprilat Anhydrous; Enalaprilat Citrate, Anhydrous; Enalaprilat, (R)-Isomer, Anhydrous; MK-422; MSD Brand of Enalaprilat; Merck Frosst Brand of Enalaprilat Anhydrous; Pres iv; Teva Brand of Enalaprilat; Xanef; Anhydrous Enalaprilat Citrate; Anhydrous, Enalaprilat; MK 422; MK422; Enalaprilic Acid; L-Proline, 1-(N-(1-carboxy-3-phenylpropyl)-L-alanyl)-, dihydrate, (S)-

Networked: 244 relevant articles (18 outcomes, 30 trials/studies)

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins
- Peptides: 22950
  - Oligopeptides: 168
    - Dipeptides: 137
      - Enalapril: 2968
        Enalaprilat: 244

Experts

1.	Xiao, Rong: 5 articles (01/2012 - 10/2007)
2.	Huang, Yue-sheng: 3 articles (01/2012 - 10/2007)
3.	Huang, Yue-Sheng: 3 articles (09/2011 - 07/2008)
4.	Dendorfer, A: 3 articles (02/2007 - 12/2001)
5.	Klimas, Jan: 2 articles (05/2015 - 08/2013)
6.	Krenek, Peter: 2 articles (05/2015 - 08/2013)
7.	Kucerova, Dana: 2 articles (05/2015 - 08/2013)
8.	Doka, Gabriel: 2 articles (05/2015 - 08/2013)
9.	Kmecova, Jana: 2 articles (05/2015 - 08/2013)
10.	Kyselovic, Jan: 2 articles (05/2015 - 08/2013)

Related Diseases

1.	Hypertension (High Blood Pressure) 08/01/1995 - "We found intravenous enalaprilat effective and safe in lowering postoperative hypertension following neurosurgery as assessed by it's effects on central haemodynamics and systemic oxygenation." 08/01/1995 - "The efficacy of intravenous enalaprilat in lowering postoperative hypertension. " 12/01/2005 - "Concurrent treatment with Enalaprilat reversed the hypertension induced by ANG II infusion (98 +/- 3 versus 155 +/- 4 mmHg; P < 0.001). " 01/01/2004 - "Thus, we conclude that intravenous enalaprilat is an effective, safe and well tolerated agent for managing severe hypertension in patients requiring an emergency reduction in blood pressure." 01/01/2004 - "Evaluation of the efficacy, safety and tolerability of intravenous enalaprilat in the treatment of grade III essential hypertension in Indian patients."
2.	Heart Failure 01/01/1986 - "The clinical significance of deesterification by the liver needs further study but minor abnormalities of liver function, such as occur in congestive heart failure, do not affect the rate of deesterification and hence the plasma enalaprilat levels. " 01/01/2003 - "Enalaprilat is the only ACE inhibitor available for parenteral use and may be particularly useful in treating hypertensive emergencies in patients with heart failure. " 07/01/2000 - "Seven patients with heart failure received a 3-hour infusion of the ACE inhibitor enalaprilat. " 02/01/2000 - "These favorable effects of enalaprilat on the coronary circulation may be of clinical significance in patients with heart failure due to nonischemic DCM. " 04/01/1999 - "Thus, in conscious dogs with heart failure, enalaprilat is effective whether the RAS is activated or not. "
3.	Renal Insufficiency (Renal Failure) 03/01/1993 - "Protective effects of enalaprilat against postischemic renal failure." 04/01/2005 - "In patients with moderate to severe renal insufficiency, a low concentration of enalaprilat afforded the same degree of renoprotection, blood pressure control and minimisation of proteinuria as a high concentration, during 12 months of follow-up. " 04/01/2005 - "Since marked inter-patient variation in concentrations of enalaprilat has been shown in patients with renal failure despite equivalent dosage of enalapril, a direct comparison of the effect of high versus low plasma concentrations of enalaprilat on the progression of renal failure was undertaken. " 05/01/1987 - "Disposition of enalapril and enalaprilat in renal insufficiency." 01/01/2000 - "Fosinoprilat exhibits significantly less accumulation than enalaprilat or lisinopril in patients with CHF and renal insufficiency, most probably because fosinoprilat is eliminated by both the kidney and liver, and increased hepatic elimination can compensate for reduced renal clearance in patients with kidney dysfunction."
4.	Myocardial Infarction 05/01/2007 - "Effects of intracoronary low-dose enalaprilat on ventricular repolarization dynamics after direct percutaneous intervention for acute myocardial infarction." 01/01/2007 - "We examined the effects of low doses of intracoronary (i.c.) enalaprilat (EN) as an adjunct to direct percutaneous coronary interventions (PCI) on reperfusion VA in the acute phase of myocardial infarction (MI). " 01/01/2007 - "Low doses of intracoronary enalaprilat suppress reperfusion-associated ventricular arrhythmias after primary percutaneous coronary interventions for acute myocardial infarction." 12/15/2001 - "Effects of intracoronary low-dose enalaprilat as an adjunct to primary percutaneous transluminal coronary angiography in acute myocardial infarction." 10/01/1991 - "We treated 48 patients with intravenous enalaprilat within 24 hours from the onset of acute myocardial infarction. "
5.	Renal Artery Obstruction (Renal Artery Stenosis) 12/01/1991 - "ACE inhibition (10 mg enalaprilic acid, intravenously) markedly improved the sensitivity of [123I]hippuran renography in 10 renovascular hypertensive dogs with a mild to moderate unilateral renal artery stenosis from 50 to 100%. " 03/01/1996 - "Enalaprilat (10 mg intravenously) in conscious dogs with renal artery stenoses produced changes in all stenotic (n = 11) but not in nonstenotic kidney 123I-hippurate renograms (n = 6). " 12/01/1992 - "Prolonged hypotension by enalaprilat in a case of renal artery stenosis." 06/01/1991 - "This study was performed to determine divided renal efferent sympathetic nerve activity from kidneys in seven patients with renin-positive, unilateral renal artery stenosis before and 30 minutes after an acute intravenous dose of 1.25 mg enalaprilat. " 07/01/1999 - "Our objective was to investigate whether the angiotensin converting enzyme inhibitor enalaprilat improves detection of hemodynamically significant renal artery stenoses in dogs. "

Related Drugs and Biologics

1.	Enalapril
2.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
3.	Angiotensin II
4.	Lisinopril (Prinivil)
5.	perindoprilat
6.	Nicardipine (Dagan)
7.	Labetalol (Normodyne)
8.	Adenosine
9.	Lactic Acid
10.	Creatine Kinase (Creatine Phosphokinase)

Related Therapies and Procedures

1.	Resuscitation
2.	Ligation
3.	Intravenous Infusions
4.	Angioplasty (Angioplasty, Transluminal)
5.	Surgical Instruments (Clip)